[1]
Sun, D.; Ong, P.J. Infectious complications in atopic dermatitis. Immunol. Allergy Clin. North Am., 2017, 37(1), 75-93.
[2]
Su, J.; Kemp, A.; Varigos, G.; Nolian, T. Atopic eczema: Its impact on the family and financial cost. Arch. Dis. Child., 1997, 76(2), 159-162.
[3]
Bieber, T.; Prölss, J. In: Clinical and Basic Immunodermatology; Gaspari, A.A.; Tyring, S.K., Eds.; Springer: London, 2008, pp. 193-206.
[4]
Leung, D.Y. Infection in atopic dermatitis. Curr. Opin. Pediatr., 2003, 15(4), 399-404.
[5]
Leyden, J.J.; Marples, R.R.; Kligman, A.M. Staphylococcus aureus in the lesions of atopic dermatitis. Br. J. Dermatol., 1974, 90(5), 525-530.
[6]
Suh, L.; Coffin, S.; Leckerman, K.H.; Gelfand, J.M.; Honig, P.J.; Yan, A.C. Methicillin-resistant Staphylococcus aureus colonization in children with atopic dermaitis. Pediatr. Dermatol., 2008, 25(5), 528-534.
[7]
Wollenberg, A.; Wetzel, S.; Burgdorf, W.H.; Haas, J. Viral infections in atopic dermatitis: Pathogenic aspects and clinical management. J. Allergy Clin. Immunol., 2003, 112(4), 667-674.
[8]
Schmid-Grendelmeier, P.; Scheynius, A.; Crameri, R. In: Allergy and Asthma in Modern Society: A Scientific Approach; Crameri, R., Ed.; Karger Publishers: Basel, 2006, Vol. 91, pp. 98-109.
[9]
Krakowski, A.C.; Eichenfield, L.F.; Dohil, M.A. Management of atopic dermatitis in the pediatric population. Pediatrics, 2008, 122(4), 812-824.
[10]
Arkwright, P.; Motala, C.; Subramanian, H.; Spergel, J.; Schneider, L.; Wollenberg, A. Management of difficult-to-treat atopic dermatitis. J. Allergy Clin. Immunol. Pract., 2013, 1(2), 142-151.
[11]
Aggarwal, B.B.; Young, J.S.; Shishodia, S. The molecular targets and therapeutic uses of curcumin in health and disease; 1st ed.;
Springer Science +Business Media: LLC; , 2007.
[12]
Maheshwari, R.; Singh, A.K.; Gaddipati, J.; Srimal, R.C. Multiple biological activities of curcumin: A short review. Life Sci., 2006, 78(18), 2081-2087.
[13]
Nguyen, T.A.; Friedman, A.J. Curcumin: a novel treatment for skin-related disorders. J. Drugs Dermatol., 2013, 12(10), 1131-1137.
[14]
Gupta, S.; Prasad, S.; Ji, H.K.; Patchva, S.; Webb, L.J.; Priyadarsini, K.I.; Aggarwal, B.B. Multitargeting by curcumin as revealed by molecular interaction studies. Nat. Prod. Rep., 2011, 28(12), 1937-1955.
[15]
Sun, J.; Zhao, Y.; Hu, J. Curcumin inhibits imiquimod-induced psoriasis-like inflammation by inhibiting IL-1beta and IL-6 production in mice. PloS One, 2013, 8(6) e67078
[16]
Moon, P.D.; Jeong, H.J.; Kim, H.M. Down-regulation of thymic stromal lymphopoietin by curcumin. Pharmacol. Rep., 2013, 65(2), 525-531.
[17]
Moghadamtousi, S.Z.; Kadir, H.A.; Hassandarvish, P.; Tajik, H.; Abubakar, S.; Zandi, K. A review on antibacterial, antiviral, and antifungal activity of curcumin. BioMed Res. Int., 2014, 2014186864
[18]
Teow, S.Y.; Liew, K.; Ali, S.A.; Khoo, A.S.; Peh, S.C. Antibacterial action of curcumin against Staphylococcus aureus: A brief review. J. Trop. Med., 2016, 20162853045
[19]
Anand, P.; Kunnumakkara, A.B.; Newman, R.A.; Aggarwal, B.B. Bioavailability of curcumin: Problems and promises. Mol. Pharm., 2007, 4(6), 807-818.
[20]
Zhai, Y.; Zhai, G. Advances in lipid-based colloid systems as drug carrier for topic delivery. J. Control. Release, 2014, 193, 90-99.
[21]
Pardeike, J.; Hommoss, A. Muller. R.H. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int. J. Pharm., 2009, 366(1-2), 170-184.
[22]
Loo, C.H.; Basri, M.; Ismail, R.; Lau, H.L.N.; Tejo, B.A.; Kanthimathi, M.S.; Hassan, H.A.; Choo, Y.M. Effect of compositions in nanostructured lipid carriers (NLC) on skin hydration and occlusion. Int. J. Nanomedicine, 2013, 8, 13.
[23]
Chen, P.; Zhang, H.; Cheng, S.; Zhai, G.; Shen, C. Development of curcumin loaded nanostructured lipid carrier based thermosensitive in situ gel for dermal delivery. Colloids Surf. A, 2016, 506, 356-362.
[24]
Shah, R.; Eldridge, D.; Palombo, E.; Harding, I. Lipid nanoparticles:
Production, characterization and stability, 1st Ed; Springer
International Publishing: Switezerland, 2015.
[25]
Kumar, A.; Sawant, K.K. Application of multiple regression analysis in optimization of anastrozole-loaded PLGA nanoparticles. J. Microencapsul., 2014, 31(2), 105-114.
[26]
Lalan, M.S.; Laddha, N.C.; Lalani, J.; Imran, M.J.; Begum, R.; Misra, A. Suppression of cytokine gene expression and improved therapeutic efficacy of microemulsion-based tacrolimus cream for atopic dermatitis. Drug Deliv. Transl. Res., 2012, 2(2), 129-141.
[27]
Phatak, A.A.; Chaudhari, P.D. Development and evaluation of Nanostructured Lipid Carrier (NLC) based topical delivery of an anti-inflammatory drug. J. Pharm. Res., 2013, 7(8), 677-685.
[28]
Lalan, M.S.; Khode, S.S.; Shah, K.S.; Patel, P.C. Preliminary development studies of halobetasol propionate organogel for management of atopic dermatitis. Int. J. Pharm. Sci. Res., 2017, 8(2), 775-783.
[29]
Joshi, M.; Patravale, V. Formulation and evaluation of nanostructured lipid carrier (NLC)–based gel of Valdecoxib. Drug Dev. Ind. Pharm., 2006, 32(8), 911-918.
[30]
Chen, Y.; Wu, Q.; Zhang, Z.; Yuan, L.; Liu, X.; Zhou, L. Preparation of curcumin-loaded liposomes and evaluation of their skin permeation and pharmacodynamics. Molecules, 2012, 17(5), 5972-5987.
[31]
Banerjee, S.; Chattopadhyay, P.; Ghosh, A.; Pathak, M.; Singh, S. Acute dermal irritation, sensitization, and acute toxicity studies of a transdermal patch for prophylaxis against (±) anatoxin-A poisoning. Int. J. Toxicol., 2016, 32(4), 308-313.
[32]
Sekizawa, J.; Yasuhara, K.; Suyama, Y.; Yamanaka, S.; Tobe, M.; Nishimura, M. A simple method for screening assessment of skin and eye irritation. J. Toxicol. Sci., 1994, 19(1), 25-35.
[33]
Negi, P.; Singh, B.; Sharma, G.; Beg, S.; Katare, O.P. Biocompatible lidocaine and prilocaine loaded-nanoemulsion system for enhanced percutaneous absorption: QbD-based optimisation, dermatokinetics and in vivo evaluation. J. Microencapsul., 2015, 32(5), 419-431.
[34]
Balouiri, M.; Sadiki, M.; Ibnsouda, S.K. Methods for in vitro evaluating antimicrobial activity: A review. J. Pharm. Anal., 2016, 6(2), 71-79.
[35]
Wang, S.; Tan, M.; Zhong, Z.; Chen, M.; Wang, Y. Nanotechnologies for curcumin: an ancient puzzler meets modern solutions. J. Nanomater., 2011, 2011 723178
[36]
Levy, M.; Schutze, W.; Fuhrer, C.; Benita, S. Characterization of diazepam submicron emulsion interface: Role of oleic acid. J. Microencapsul., 1994, 11(1), 79-92.
[37]
Aditya, N.; Shim, K.; Lee, I.; Lee, Y.; Ko, S. Curcumin and genistein loaded nanostructured lipid carriers: In vitro digestion and antiprostate cancer activity. J. Agric. Food Chem., 2013, 61(8), 1878-1883.
[38]
Han, F.; Yin, R.; Che, X.; Yuan, J.; Cui, Y.; Yin, H.; Li, S. Nanostructured lipid carriers (NLC) based topical gel of flurbiprofen: design, characterization and in vivo evaluation. Int. J. Pharm., 2012, 439(1-2), 349-357.
[39]
Fang, C.; Al-Suwayeh, S.S.; Fang, J.Y. Nanostructured lipid carriers (NLCs) for drug delivery and targeting. Recent Pat. Nanotechnol., 2013, 7(1), 41-55.
[40]
Rai, D.; Singh, J.K.; Roy, N.; Panda, D. Curcumin inhibits FtsZ assembly: An attractive mechanism for its antibacterial activity. Biochem. J., 2008, 410(1), 147-155.
[41]
Kim, K.H.; Han, J.H.; Chung, J.H.; Cho, K.H.; Eun, H.C. Role of staphylococcal superantigen in atopic dermatitis: Influence on keratinocytes. J. Korean Med. Sci., 2006, 21(2), 315-323.
[42]
Mun, S.H.; Kim, S.B.; Kong, R.; Choi, J.G.; Kim, Y.C.; Shin, D.W.; Kang, O.H.; Kwon, D.Y. Curcumin reverse methicillin resistance in Staphylococcus aureus. Molecules, 2014, 19(11), 18283-18295.
[43]
Singh, R.; Chandra, R.; Bose, M.; Luthra, P.M. Antibacterial activity of Curcuma longa rhizome extract on pathogenic bacteria. Curr. Sci., 2002, 83(6), 737-740.
20
1